A high-density lipoprotein-mediated drug delivery system

Sviridov, 2015, High-density lipoprotein mimetics: promises and challenges, Biochem. J., 472, 249, 10.1042/BJ20150832 Tabet, 2011, Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages, Arterioscler. Thromb. Vasc. Biol., 31, 1192, 10.1161/ATVBAHA.110.222000 Yvan-Charvet, 2010, ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis, Circ. Res., 106, 1861, 10.1161/CIRCRESAHA.110.217281 Toth, 2013, High-density lipoproteins: a consensus statement from the National Lipid Association, J. Clin. Lipidol., 7, 484, 10.1016/j.jacl.2013.08.001 Boekholdt, 2013, Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis, Circulation, 128, 1504, 10.1161/CIRCULATIONAHA.113.002670 Touboul, 2014, HDL-C, triglycerides and carotid IMT: a meta-analysis of 21,000 patients with automated edge detection IMT measurement, Atherosclerosis, 232, 65, 10.1016/j.atherosclerosis.2013.10.011 Halcox, 2015, E.s. committee, Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm, Eur. J. Prev. Cardiol., 22, 200, 10.1177/2047487313507680 Hippisley-Cox, 2013, Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study, BMJ, 346, f2573, 10.1136/bmj.f2573 Verges, 2014, Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study, J. Clin. Endocrinol. Metab., 99, 4281, 10.1210/jc.2014-2365 Mann, 1991, Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia, J. Clin. Invest., 88, 2059, 10.1172/JCI115535 Liinamaa, 1997, Altered transfer of cholesteryl esters and phospholipids in plasma from alcohol abusers, Arterioscler. Thromb. Vasc. Biol., 17, 2940, 10.1161/01.ATV.17.11.2940 Rashid, 2007, Effect of obesity on high-density lipoprotein metabolism, Obesity, 15, 2875, 10.1038/oby.2007.342 Tsimihodimos, 2010, Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia, Atherosclerosis, 208, 506, 10.1016/j.atherosclerosis.2009.07.038 Holzer, 2012, Psoriasis alters HDL composition and cholesterol efflux capacity, J. Lipid Res., 53, 1618, 10.1194/jlr.M027367 Raterman, 2013, HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab, Ann. Rheum. Dis., 72, 560, 10.1136/annrheumdis-2011-201228 Gangadharan, 2012, Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study, PLoS One, 7, 10.1371/journal.pone.0039603 Furberg, 2005, Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study, Cancer Epidemiol. Biomarkers Prev., 14, 33, 10.1158/1055-9965.33.14.1 Melvin, 2012, Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study, Cancer Epidemiol. Biomarkers Prev., 21, 1381, 10.1158/1055-9965.EPI-12-0188 Tamura, 2012, Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients, J. Gastroenterol. Hepatol., 27, 1635, 10.1111/j.1440-1746.2012.07189.x Chenevard, 2012, Reconstituted HDL in acute coronary syndromes, Cardiovasc. Ther., 30, e51, 10.1111/j.1755-5922.2010.00221.x Krause, 2013, Reconstituted HDL for the acute treatment of acute coronary syndrome, Curr. Opin. Lipidol., 24, 480, 10.1097/MOL.0000000000000020 Calkin, 2009, Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux, Circulation, 120, 2095, 10.1161/CIRCULATIONAHA.109.870709 Drew, 2009, High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus, Circulation, 119, 2103, 10.1161/CIRCULATIONAHA.108.843219 Foit, 2015, Synthetic high-density lipoprotein-like nanoparticles for cancer therapy, Expert. Rev. Anticancer. Ther., 15, 27, 10.1586/14737140.2015.990889 McMahon, 2015, Synthetic high-density lipoprotein-like nanoparticles as cancer therapy, Cancer Treat. Res., 166, 129, 10.1007/978-3-319-16555-4_6 Patel, 2009, Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes, J. Am. Coll. Cardiol., 53, 962, 10.1016/j.jacc.2008.12.008 Duivenvoorden, 2014, A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation, Nat. Commun., 5, 3065, 10.1038/ncomms4065 Tardy, 2014, CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice, Atherosclerosis, 232, 110, 10.1016/j.atherosclerosis.2013.10.018 Lou, 2005, High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells, World J. Gastroenterol., 11, 954, 10.3748/wjg.v11.i7.954 Oda, 2006, Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B, J. Lipid Res., 47, 260, 10.1194/jlr.D500033-JLR200 Burgess, 2010, A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties, Int. J. Pharm., 399, 148, 10.1016/j.ijpharm.2010.07.057 Damiano, 2013, Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery, Adv. Drug Deliv. Rev., 65, 649, 10.1016/j.addr.2012.07.013 Shahzad, 2011, Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles, Neoplasia, 13, 309, 10.1593/neo.101372 Jones, 2011, “Sticky” and “promiscuous”, the yin and yang of apolipoprotein A-I termini in discoidal high-density lipoproteins: a combined computational–experimental approach, Biochemistry, 50, 2249, 10.1021/bi101301g Camont, 2011, Biological activities of HDL subpopulations and their relevance to cardiovascular disease, Trends Mol. Med., 17, 594, 10.1016/j.molmed.2011.05.013 Davidson, 2007, The structure of apolipoprotein A-I in high density lipoproteins, J. Biol. Chem., 282, 22249, 10.1074/jbc.R700014200 Ajees, 2006, Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases, Proc. Natl. Acad. Sci. U. S. A., 103, 2126, 10.1073/pnas.0506877103 Segrest, 1999, A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein, J. Biol. Chem., 274, 31755, 10.1074/jbc.274.45.31755 Silva, 2005, A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins, Biochemistry, 44, 8600, 10.1021/bi050421z Borhani, 1997, Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation, Proc. Natl. Acad. Sci. U. S. A., 94, 12291, 10.1073/pnas.94.23.12291 Koppaka, 1999, The structure of human lipoprotein A-I. Evidence for the “belt” model, J. Biol. Chem., 274, 14541, 10.1074/jbc.274.21.14541 Ibanez, 2012, Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type), Atherosclerosis, 220, 72, 10.1016/j.atherosclerosis.2011.10.006 Rocco, 2010, Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL, J. Mol. Graph. Model., 29, 406, 10.1016/j.jmgm.2010.08.002 Gursky, 2013, Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I, J. Lipid Res., 54, 3244, 10.1194/jlr.R037911 Petrlova, 2012, The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils, J. Lipid Res., 53, 390, 10.1194/jlr.M020883 Lagerstedt, 2007, Mapping the structural transition in an amyloidogenic apolipoprotein A-I, Biochemistry, 46, 9693, 10.1021/bi7005493 Anantharamaiah, 1985, Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine, J. Biol. Chem., 260, 10248, 10.1016/S0021-9258(17)39238-4 Datta, 2001, Effects of increasing hydrophobicity on the physical–chemical and biological properties of a class A amphipathic helical peptide, J. Lipid Res., 42, 1096, 10.1016/S0022-2275(20)31599-6 Navab, 2013, Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid, J. Lipid Res., 54, 3403, 10.1194/jlr.M042051 Navab, 2002, Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol, Circulation, 105, 290, 10.1161/hc0302.103711 Van Lenten, 2004, D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes, Circulation, 110, 3252, 10.1161/01.CIR.0000147232.75456.B3 Van Lenten, 2002, Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide, Circulation, 106, 1127, 10.1161/01.CIR.0000030182.35880.3E D'Souza, 2010, Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein, Circ. Res., 107, 217, 10.1161/CIRCRESAHA.110.216507 Rudman, 1968, Observations on the protein components of human plasma high- and low-density lipoproteins, Biochemistry, 7, 3136, 10.1021/bi00849a017 Shore, 1968, Heterogeneity in protein subunits of human serum high-density lipoproteins, Biochemistry, 7, 2773, 10.1021/bi00848a011 Davidsson, 2010, Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins, Arterioscler. Thromb. Vasc. Biol., 30, 156, 10.1161/ATVBAHA.108.179317 Zannis, 2004, Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer, Curr. Opin. Lipidol., 15, 151, 10.1097/00041433-200404000-00008 Zannis, 1985, Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages, Biochemistry, 24, 4450, 10.1021/bi00337a028 Zannis, 2006, Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL, J. Mol. Med., 84, 276, 10.1007/s00109-005-0030-4 Thacker, 2015, Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice, J. Lipid Res., 56, 1282, 10.1194/jlr.M048629 Jonas, 2000, Lecithin cholesterol acyltransferase, Biochim. Biophys. Acta, 1529, 245, 10.1016/S1388-1981(00)00153-0 van Tol, 2002, Phospholipid transfer protein, Curr. Opin. Lipidol., 13, 135, 10.1097/00041433-200204000-00004 Barter, 2003, Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 23, 160, 10.1161/01.ATV.0000054658.91146.64 Santamarina-Fojo, 2004, Hepatic lipase, lipoprotein metabolism, and atherogenesis, Arterioscler. Thromb. Vasc. Biol., 24, 1750, 10.1161/01.ATV.0000140818.00570.2d Massey, 2008, Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I, Biochim. Biophys. Acta, 1781, 245, 10.1016/j.bbalip.2008.03.003 Nguyen, 2012, Spontaneous remodeling of HDL particles at acidic pH enhances their capacity to induce cholesterol efflux from human macrophage foam cells, J. Lipid Res., 53, 2115, 10.1194/jlr.M028118 Rye, 1994, The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins, J. Biol. Chem., 269, 10298, 10.1016/S0021-9258(17)34060-7 Maugeais, 2003, Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase, Circulation, 108, 2121, 10.1161/01.CIR.0000092889.24713.DC Wolfrum, 2005, Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis, Nat. Med., 11, 418, 10.1038/nm1211 Lusa, 1996, The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion, Biochem. J., 313, 275, 10.1042/bj3130275 Pagler, 2006, SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux, J. Biol. Chem., 281, 11193, 10.1074/jbc.M510261200 Rohrl, 2013, HDL endocytosis and resecretion, Biochim. Biophys. Acta, 1831, 1626, 10.1016/j.bbalip.2013.07.014 Nakamura, 2004, Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein, J. Biol. Chem., 279, 45980, 10.1074/jbc.M408652200 Martinez, 2003, Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis, Nature, 421, 75, 10.1038/nature01250 Jackson, 1975, A comparative study on the removal of cellular lipids from Landschutz ascites cells by human plasma apolipoproteins, J. Biol. Chem., 250, 7204, 10.1016/S0021-9258(19)40929-0 Annema, 2012, Regulation of reverse cholesterol transport—a comprehensive appraisal of available animal studies, Nutr. Metab., 9, 25, 10.1186/1743-7075-9-25 Rosenson, 2012, Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport, Circulation, 125, 1905, 10.1161/CIRCULATIONAHA.111.066589 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Lewis, 2010, Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease, J. Biol. Chem., 285, 36958, 10.1074/jbc.M110.127829 Robert, 2016, Reconstituted high-density lipoproteins acutely reduce soluble brain Abeta levels in symptomatic APP/PS1 mice, Biochim. Biophys. Acta, 1862, 1027, 10.1016/j.bbadis.2015.10.005 Shaw, 2008, Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque, Circ. Res., 103, 1084, 10.1161/CIRCRESAHA.108.182063 Liu, 2013, HDL drug carriers for targeted therapy, Clin. Chim. Acta, 415, 94, 10.1016/j.cca.2012.10.008 Wolfrum, 2007, Mechanisms and optimization of in vivo delivery of lipophilic siRNAs, Nat. Biotechnol., 25, 1149, 10.1038/nbt1339 Zhang, 2009, Biomimetic nanocarrier for direct cytosolic drug delivery, Angew. Chem., 48, 9171, 10.1002/anie.200903112 Sherman, 2010, Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis, Cardiol. Rev., 18, 141, 10.1097/CRD.0b013e3181c4b508 Murakami, 2010, Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles, Nanomedicine, 5, 867, 10.2217/nnm.10.66 Iovannisci, 2009, Targeting nanodisks via a single chain variable antibody–apolipoprotein chimera, Biochem. Biophys. Res. Commun., 379, 466, 10.1016/j.bbrc.2008.12.077 Uno, 2011, High-density lipoprotein facilitates in vivo delivery of alpha-tocopherol-conjugated short-interfering RNA to the brain, Hum. Gene Ther., 22, 711, 10.1089/hum.2010.083 Ryan, 2010, Nanobiotechnology applications of reconstituted high density lipoprotein, J. Nanobiotechnol., 8, 28, 10.1186/1477-3155-8-28 Redmond, 2007, All-trans-retinoic acid nanodisks, Int. J. Pharm., 339, 246, 10.1016/j.ijpharm.2007.02.033 Park, 2011, Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy, Oncology, 25, 733 Ghosh, 2011, Curcumin nanodisks: formulation and characterization, Nanomedicine, 7, 162, 10.1016/j.nano.2010.08.002 Wang, 2013, Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins, Drug Deliv., 20, 356, 10.3109/10717544.2013.834418 Zhang, 2013, A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation, Asian J. Pharm. Sci., 8, 11, 10.1016/j.ajps.2013.07.002 Segrest, 2013, MD simulations suggest important surface differences between reconstituted and circulating spherical HDL, J. Lipid Res., 54, 2718, 10.1194/jlr.M039206 Zhang, 2012, Tanshinone IIA-loaded reconstituted high density lipoproteins: atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits, Pharmazie, 67, 324 Sabnis, 2012, Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles, Int. J. Nanomedicine, 7, 975 Sabnis, 2013, Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma, Front. Pediatr., 1, 6, 10.3389/fped.2013.00006 McConathy, 2008, Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel, Anti-Cancer Drugs, 19, 183, 10.1097/CAD.0b013e3282f1da86 Yin, 2014, Non-viral vectors for gene-based therapy, Nat. Rev. Genet., 15, 541, 10.1038/nrg3763 Dobrovolskaia, 2015, Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics, Expert Opin. Drug Deliv., 12, 1163, 10.1517/17425247.2015.1042857 Bali, 2014, Noncoding RNAs: key molecules in understanding and treating pain, Trends Mol. Med., 20, 437, 10.1016/j.molmed.2014.05.006 Vickers, 2011, MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins, Nat. Cell Biol., 13, 423, 10.1038/ncb2210 Soutschek, 2004, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, 432, 173, 10.1038/nature03121 Tripathy, 2014, High density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis, Part. Part. Syst. Charact., 31, 1141, 10.1002/ppsc.201400036 Ding, 2012, A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy, Biomaterials, 33, 8893, 10.1016/j.biomaterials.2012.08.057 Nakayama, 2012, Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles, Mol. Ther., 20, 1582, 10.1038/mt.2012.33 Lee, 2009, Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice, Biochem. Biophys. Res. Commun., 378, 192, 10.1016/j.bbrc.2008.11.029 Janas, 2006, Specific RNA binding to ordered phospholipid bilayers, Nucleic Acids Res., 34, 2128, 10.1093/nar/gkl220 Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc. Natl. Acad. Sci. U. S. A., 105, 10513, 10.1073/pnas.0804549105 Qiu, 2007, Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules, Nat. Struct. Mol. Biol., 14, 106, 10.1038/nsmb1197 McMahon, 2011, Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery, Nano Lett., 11, 1208, 10.1021/nl1041947 Perez-Medina, 2015, PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles, J. Nucl. Med., 56, 1272, 10.2967/jnumed.115.158956 Shen, 2015, Diagnostic magnetic resonance imaging of atherosclerosis in apolipoprotein E knockout mouse model using macrophage-targeted gadolinium-containing synthetic lipopeptide nanoparticles, PLoS One, 10, 10.1371/journal.pone.0143453 Zhang, 2010, HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting, Small, 6, 430, 10.1002/smll.200901515 Sanchez-Gaytan, 2015, HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages, Bioconjug. Chem., 26, 443, 10.1021/bc500517k Fedeli, 2014, Variations of the corona HDL:albumin ratio determine distinct effects of amorphous SiO2 nanoparticles on monocytes and macrophages in serum, Nanomedicine, 9, 2481, 10.2217/nnm.14.22 Gu, 2011, Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells, AAPS PharmSciTech, 12, 1200, 10.1208/s12249-011-9668-0 Huang, 2015, GM1-modified lipoprotein-like nanoparticle: multifunctional nanoplatform for the combination therapy of Alzheimer's disease, ACS Nano, 9, 10801, 10.1021/acsnano.5b03124 Murakami, 2015, Structural and functional changes in high-density lipoprotein induced by chemical modification, Biomater. Sci., 3, 712, 10.1039/C4BM00402G Fischer, 2014, Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform, PLoS One, 9, 10.1371/journal.pone.0093342 Acton, 1996, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor, Science, 271, 518, 10.1126/science.271.5248.518 Azhar, 1998, Simultaneous induction of an HDL receptor protein (SR-BI) and the selective uptake of HDL-cholesteryl esters in a physiologically relevant steroidogenic cell model, J. Lipid Res., 39, 1616, 10.1016/S0022-2275(20)32191-X During, 2005, Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe, J. Nutr., 135, 2305, 10.1093/jn/135.10.2305 Rigotti, 1995, The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids, J. Biol. Chem., 270, 16221, 10.1074/jbc.270.27.16221 Pei, 2013, SR-BI in bone marrow derived cells protects mice from diet induced coronary artery atherosclerosis and myocardial infarction, PLoS One, 8, 10.1371/journal.pone.0072492 Mineo, 2003, HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action, Trends Cardiovasc. Med., 13, 226, 10.1016/S1050-1738(03)00098-7 Grewal, 2003, High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras, J. Biol. Chem., 278, 16478, 10.1074/jbc.C300085200 Tolle, 2008, HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production, Arterioscler. Thromb. Vasc. Biol., 28, 1542, 10.1161/ATVBAHA.107.161042 Graf, 1999, The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae, J. Biol. Chem., 274, 12043, 10.1074/jbc.274.17.12043 Zheng, 2013, Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles, Theranostics, 3, 477, 10.7150/thno.6617 Yang, 2013, Biomimetic, synthetic HDL nanostructures for lymphoma, Proc. Natl. Acad. Sci. U. S. A., 110, 2511, 10.1073/pnas.1213657110 Lin, 2012, Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles, Nanomedicine, 7, 1813, 10.2217/nnm.12.73 Lacko, 2002, High density lipoprotein complexes as delivery vehicles for anticancer drugs, Anticancer Res., 22, 2045 Oram, 2002, The cholesterol mobilizing transporter ABCA1 as a new therapeutic target for cardiovascular disease, Trends Cardiovasc. Med., 12, 170, 10.1016/S1050-1738(02)00159-7 Boadu, 2006, The role of vesicular transport in ABCA1-dependent lipid efflux and its connection with NPC pathways, J. Mol. Med., 84, 266, 10.1007/s00109-005-0001-9 Hassan, 2007, Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis, J. Lipid Res., 48, 2428, 10.1194/jlr.M700206-JLR200 Vedhachalam, 2007, ABCA1-induced cell surface binding sites for ApoA-I, Arterioscler. Thromb. Vasc. Biol., 27, 1603, 10.1161/ATVBAHA.107.145789 Du, 2015, HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export, Circ. Res., 116, 1133, 10.1161/CIRCRESAHA.116.305485 Landry, 2006, ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions, J. Biol. Chem., 281, 36091, 10.1074/jbc.M602247200 Nandi, 2009, ABCA1-mediated cholesterol efflux generates microparticles in addition to HDL through processes governed by membrane rigidity, J. Lipid Res., 50, 456, 10.1194/jlr.M800345-JLR200 Mulya, 2007, Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1, Arterioscler. Thromb. Vasc. Biol., 27, 1828, 10.1161/ATVBAHA.107.142455 Negi, 2013, A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease, J. Clin. Lipidol., 7, 82, 10.1016/j.jacl.2012.09.004 Brunham, 2015, Clinical, biochemical, and molecular characterization of novel mutations in ABCA1 in families with Tangier disease, JIMD Rep., 18, 51, 10.1007/8904_2014_348 Oram, 2002, ABCA1 as a new therapeutic target for treating cardiovascular disease, Drug News Perspect., 15, 24, 10.1358/dnp.2002.15.1.840027 Huang, 2013, The target of regulating the ATP-binding cassette A1 protein (ABCA1): promoting ABCA1-mediated cholesterol efflux in different cells, Curr. Pharm. Biotechnol., 14, 623, 10.2174/138920101131400228 Lindegaard, 2008, Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith–Lemli–Opitz syndrome, Hum. Mol. Genet., 17, 3806, 10.1093/hmg/ddn278 Chou, 2015, Hypermethylation of the TGF-beta target, ABCA1 is associated with poor prognosis in ovarian cancer patients, Clin. Epigenetics, 7, 1, 10.1186/s13148-014-0036-2 Christoffersen, 2006, Isolation and characterization of human apolipoprotein M-containing lipoproteins, J. Lipid Res., 47, 1833, 10.1194/jlr.M600055-JLR200 Mulya, 2010, Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1, J. Lipid Res., 51, 514, 10.1194/jlr.M002162 Liu, 2014, Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein, J. Biol. Chem., 289, 2801, 10.1074/jbc.M113.499913 Christoffersen, 2008, Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice, J. Biol. Chem., 283, 1839, 10.1074/jbc.M704576200 Elsoe, 2013, Apolipoprotein M promotes mobilization of cellular cholesterol in vivo, Biochim. Biophys. Acta, 1831, 1287, 10.1016/j.bbalip.2013.04.009 Wilkerson, 2012, Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1, J. Biol. Chem., 287, 44645, 10.1074/jbc.M112.423426 Christoffersen, 2011, Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M, Proc. Natl. Acad. Sci. U. S. A., 108, 9613, 10.1073/pnas.1103187108 Karuna, 2011, Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism, Atherosclerosis, 219, 855, 10.1016/j.atherosclerosis.2011.08.049 Blaho, 2015, HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation, Nature, 523, 342, 10.1038/nature14462 Siow, 2010, Intracellular localization of sphingosine kinase 1 alters access to substrate pools but does not affect the degradative fate of sphingosine-1-phosphate, J. Lipid Res., 51, 2546, 10.1194/jlr.M004374 Maceyka, 2005, SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism, J. Biol. Chem., 280, 37118, 10.1074/jbc.M502207200 Spiegel, 2002, Sphingosine 1-phosphate, a key cell signaling molecule, J. Biol. Chem., 277, 25851, 10.1074/jbc.R200007200 Mandala, 2001, Sphingosine-1-phosphate phosphatases, Prostaglandins, 64, 143, 10.1016/S0090-6980(01)00111-3 Bourquin, 2010, Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism, Structure, 18, 1054, 10.1016/j.str.2010.05.011 Hisano, 2011, The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720, J. Biol. Chem., 286, 1758, 10.1074/jbc.M110.171116 Lee, 2007, A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC), Prostaglandins Other Lipid Mediat., 84, 154, 10.1016/j.prostaglandins.2007.08.001 Wang, 2008, S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells, Mol. Cancer Ther., 7, 1993, 10.1158/1535-7163.MCT-08-0088 Maceyka, 2012, Sphingosine-1-phosphate signaling and its role in disease, Trends Cell Biol., 22, 50, 10.1016/j.tcb.2011.09.003 Pyne, 2012, Sphingosine 1-phosphate signalling in cancer, Biochem. Soc. Trans., 40, 94, 10.1042/BST20110602 Maceyka, 2014, Sphingolipid metabolites in inflammatory disease, Nature, 510, 58, 10.1038/nature13475 Wang, 2014, FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury, Crit. Care Med., 42, e189, 10.1097/CCM.0000000000000097 Oo, 2007, Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor, J. Biol. Chem., 282, 9082, 10.1074/jbc.M610318200 Pinschewer, 2000, FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory, J. Immunol., 164, 5761, 10.4049/jimmunol.164.11.5761 Nofer, 2007, FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice, Circulation, 115, 501, 10.1161/CIRCULATIONAHA.106.641407 Klingenberg, 2007, Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol., 27, 2392, 10.1161/ATVBAHA.107.149476 Das, 2014, Delivery of S1P receptor-targeted drugs via biodegradable polymer scaffolds enhances bone regeneration in a critical size cranial defect, J. Biomed. Mater. Res. A, 102, 1210, 10.1002/jbm.a.34779 Cannon, 2012, Targeting blood–brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain, Proc. Natl. Acad. Sci. U. S. A., 109, 15930, 10.1073/pnas.1203534109 Cheng, 2015, The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment, Cell. Mol. Immunol., 12, 681, 10.1038/cmi.2014.59 McDonald, 2010, The sphingosine kinase inhibitor N,N-dimethylsphingosine inhibits neointimal hyperplasia, Br. J. Pharmacol., 159, 543, 10.1111/j.1476-5381.2009.00533.x Seo, 2012, Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways, J. Immunol., 188, 4759, 10.4049/jimmunol.1102754 Yang, 2015, SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo, Biochem. Biophys. Res. Commun., 460, 903, 10.1016/j.bbrc.2015.03.114 John, 2014, S1P-dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection, Immunity, 41, 440, 10.1016/j.immuni.2014.07.013 Sabbadini, 2011, Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration, Br. J. Pharmacol., 162, 1225, 10.1111/j.1476-5381.2010.01118.x Parton, 2007, The multiple faces of caveolae, Nat. Rev. Mol. Cell Biol., 8, 185, 10.1038/nrm2122 Couet, 2001, Cell biology of caveolae and caveolin, Adv. Drug Deliv. Rev., 49, 223, 10.1016/S0169-409X(01)00139-9 Cohen, 2004, Role of caveolae and caveolins in health and disease, Physiol. Rev., 84, 1341, 10.1152/physrev.00046.2003 Fielding, 2000, Cholesterol and caveolae: structural and functional relationships, Biochim. Biophys. Acta, 1529, 210, 10.1016/S1388-1981(00)00150-5 Frank, 2001, Adenovirus-mediated expression of caveolin-1 in mouse liver increases plasma high-density lipoprotein levels, Biochemistry, 40, 10892, 10.1021/bi0106437 Razani, 2002, Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities, J. Biol. Chem., 277, 8635, 10.1074/jbc.M110970200 Fraser, 1995, Lipoproteins and the liver sieve: the role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis, Hepatology, 21, 863 Storey, 2007, Selective cholesterol dynamics between lipoproteins and caveolae/lipid rafts, Biochemistry, 46, 13891, 10.1021/bi700690s Heimerl, 2008, Caveolin-1 deficiency alters plasma lipid and lipoprotein profiles in mice, Biochem. Biophys. Res. Commun., 367, 826, 10.1016/j.bbrc.2008.01.010 Lin, 2007, Molecular interaction between caveolin-1 and ABCA1 on high-density lipoprotein-mediated cholesterol efflux in aortic endothelial cells, Cardiovasc. Res., 75, 575, 10.1016/j.cardiores.2007.04.012 Chao, 2005, Cellular localization and interaction of ABCA1 and caveolin-1 in aortic endothelial cells after HDL incubation, Biochem. Biophys. Res. Commun., 332, 743, 10.1016/j.bbrc.2005.05.019 Lin, 2014, Imaging the cytosolic drug delivery mechanism of HDL-like nanoparticles, Pharm. Res., 31, 1438, 10.1007/s11095-013-1046-z Lopes-de-Araujo, 2016, Oxaprozin-loaded lipid nanoparticles towards overcoming NSAIDs side-effects, Pharm. Res., 33, 301, 10.1007/s11095-015-1788-x Zhu, 2015, Enhanced anti-metastatic activity of etoposide using layered double hydroxide nano particles, J. Biomed. Nanotechnol., 11, 2158, 10.1166/jbn.2015.2164 Tariq, 2016, Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: pharmacokinetic and pharmacodynamic investigations, Int. J. Pharm., 501, 18, 10.1016/j.ijpharm.2016.01.054 Garnett, 2015, Caveolae as a target to quench autoinduction of the metastatic phenotype in lung cancer, J. Cancer Res. Clin. Oncol. Yin, 2015, Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid, Acta Biomater., 26, 274, 10.1016/j.actbio.2015.08.029 Neves, 2016, Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery, J. Colloid Interface Sci., 463, 258, 10.1016/j.jcis.2015.10.057 Murakami, 2012, Phospholipid nanodisc engineering for drug delivery systems, Biotechnol. J., 7, 762, 10.1002/biot.201100508